Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure - Trial NCT06327698
Access comprehensive clinical trial information for NCT06327698 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Cancer Hospital and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hunan Cancer Hospital
Timeline & Enrollment
Phase 2
May 15, 2024
May 31, 2027
Primary Outcome
Response Rate
Summary
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the
 effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of
 locally advanced or metastatic melanoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06327698
Non-Device Trial